With Special Tax Suspended, Medical Device Firms Reap Big Savings

U.S. manufacturers of medical devices started 2016 with a windfall — a two-year suspension of a controversial tax on their revenue.

Medical devices include a wide range of products and machines used in medical care, such as tongue depressors, endoscopes and MRI scanners, for example. Manufacturers said the tax on devices hurt their business. The Congressional Research Service estimates companies paid out $2.4 billion in 2014.

“When this tax went into place, it forced us to make cuts and sustain those cuts,” said George Montague, chief financial officer of Minnesota-based Smiths Medical. His firm takes in more than $1 billion a year for its specialty medical products.

Smiths Medical had paid $10 million a year in medical device taxes, Montague said, “and so now we’re getting that funding back.” He insisted the money will go into building the business.

This story is part of a partnership that includes Minnesota Public Radio, NPR and Kaiser Health News. It can be republished for free. (details)

“We’re making significant investment in our product portfolio — in improving our product portfolio,” Montague said. “And what this enables us to do is accelerate some of that investment.”

The medical technology industry has branded the device tax a job-killer, though that claim has been disputed. Montague said Smiths Medical will now be adding new jobs, but he doesn’t know how many.

Minnesota is home to a concentration of device makers, and U.S. Rep. Erik Paulsen, R-Minn., is a leading opponent of the tax. He said suspending it for two years could provide a major boost to Minnesota’s economy.

“There are estimates that because of Minnesota’s high concentration in this sector — essentially the largest in the world in a concentrated environment — that Minnesota would be paying 25 percent of the tax,” Paulsen said. “That’s a big deal to our economy.”

Bob Paulson is CEO of NxThera, a small firm in Minnesota that makes devices involved in the treatment of urological conditions. His company had only been paying the device tax since November, he said, when NxThera started selling products in the United States. The tax made it harder to find financing, he said, because investors balked at putting their money into an industry that’s been singled out to pay a tax. Thanks to the tax hiatus, he said, he now plans to enlarge his staff of 43 researchers and sales people.

“It absolutely means additional money that we can invest in both of those areas,” he said.

Still, some industry analysts questioned whether suspending the tax will significantly boost the number of jobs created.

The Congressional Research Service concluded the tax was having fairly minor effects on employment, changing payrolls by no more than two-tenths of 1 percent. Still, the same report called the tax difficult to justify and noted that such excise taxes are typically put in place to discourage a particular behavior, such as smoking.

Jason McGorman, a senior analyst with Bloomberg Intelligence, said the suspension won’t really change what big companies are doing, but will help their bottom lines. Big, publicly traded firms also might return the money to shareholders by buying up their own shares, he said.

“Smaller companies felt a bigger tax bite than the giants, so they are more likely to put the tax savings back into the business,” McGorman said.

Industry analyst Brooks West, of Piper Jaffray, said device makers would be smart to reinvest the windfall.

“Politically, they better spend this money on R-and-D,” West said, “or the government can look at this and say, you know, ‘Look, if you just pass this on to the shareholders, we’re going to reimpose the tax.’ ”

But Rep. Paulsen said he doubts the tax will return. He’s optimistic the two-year tax suspension will become a permanent repeal.

This story is part of a reporting partnership with Minnesota Public Radio, NPR and Kaiser Health News.